In the United States, CJC-1295 with DAC and CJC-1295 without DAC are legally available for purchase strictly as laboratory research chemicals. PX1 Research supplies high-purity GHRH analogs verified by lot-specific third-party HPLC/MS and endotoxin testing, produced under stringent US manufacturing protocols, and dispatched same-day M–F from California and Arizona facilities.
In the United States, CJC-1295 with DAC and CJC-1295 without DAC are legally available for purchase strictly as laboratory research chemicals. PX1 Research supplies high-purity GHRH analogs verified by lot-specific third-party HPLC/MS and endotoxin testing, produced under stringent US manufacturing protocols, and dispatched same-day M–F from California and Arizona facilities.
CJC-1295 is an engineered peptide analog of growth hormone-releasing hormone (GHRH) widely studied in preclinical research to examine pituitary somatotroph stimulation and downstream insulin-like growth factor 1 (IGF-1) expression. The addition of Drug Affinity Complex (DAC) fundamentally alters the peptide's half-life by enabling covalent binding to circulating serum albumin, whereas CJC-1295 without DAC (also designated as modified GRF 1-29) exhibits a significantly shorter duration of action suitable for pulse-like secretagogue studies.
Under US federal regulations, both variants remain unscheduled and legally accessible to qualified institutional and independent researchers when acquired strictly for in vitro, analytical, and animal model evaluations. They are not approved for clinical administration, medical diagnostics, or human consumption. Laboratories evaluating secretagogue dynamics frequently compare these variants against alternative peptides like Sermorelin or pair them with growth hormone secretagogue receptor (GHSR) agonists such as Ipamorelin.
To ensure reproducible assay results, laboratories require full analytical transparency. PX1 Research provides batch-specific certificates of analysis (COAs) detailing purity via reverse-phase high-performance liquid chromatography (RP-HPLC), molecular identity via mass spectrometry (MS), and micro-quantity endotoxin screening for every batch.
Understanding the legal landscape surrounding growth hormone-releasing hormone analogs requires distinguishing between regulated pharmaceutical substances and non-controlled laboratory reagents. Neither CJC-1295 with DAC nor CJC-1295 without DAC is listed as a scheduled controlled substance under the US Controlled Substances Act (CSA). Consequently, researchers can legally buy CJC-1295 without DAC across all 50 states without a DEA license, provided the material is dedicated exclusively to non-clinical scientific research.
Regulatory compliance hinges upon end-use intent and vendor labeling standards. The US Food and Drug Administration (FDA) monitors the sale of unapproved peptides to prevent unauthorized clinical marketing or human administration. When sourced from certified domestic vendors like PX1 Research, peptides are verified for chemical identity and supplied with strict explicit research-use-only (RUO) parameters. Institutional purchasing agents and laboratory managers must maintain clear documentation that these compounds are used exclusively in analytical test systems, cellular models, or approved animal studies.
Researchers conducting international studies should verify local regional guidelines, as regulatory classification of synthetic secretagogues can vary across international jurisdictions. In the US, maintaining adherence to RUO standards ensures full compliance for laboratory procurement.
CJC-1295 without DAC is a 29-amino-acid synthetic peptide modified from the native GHRH sequence (specifically GHRH 1-29). The molecule incorporates four specific amino acid substitutions—D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27—designed to improve enzymatic resistance against dipeptidyl peptidase-IV (DPP-IV) degradation relative to endogenous GHRH.
In cell culture and preclinical models, CJC-1295 without DAC acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR) located on pituitary somatotrophs. Activation of GHRHR stimulates intracellular adenylate cyclase, elevating cyclic adenosine monophosphate (cAMP) levels and triggering protein kinase A (PKA) signaling cascades. This pathway promotes the transcription and pulsatile exocytosis of endogenous growth hormone (GH).
Preclinical studies suggest that because CJC-1295 without DAC lacks the albumin-binding moiety, its biological half-life in rodent models is approximately 30 minutes. This concise kinetic profile allows researchers to simulate natural physiological GH pulses without inducing the constant baseline receptor occupation associated with long-acting DAC complexes. Qualified investigative teams can review high-purity specifications directly on the CJC-1295 without DAC product page.
The primary distinction between CJC-1295 DAC and CJC-1295 without DAC centers on the inclusion of a maleimidopropionic acid reactive group attached via a lysine linker at the C-terminus. This Drug Affinity Complex (DAC) covalently attaches to the free cysteine-34 residue of serum albumin immediately following administration in animal models.
This albumin-binding mechanism drastically alters the pharmacokinetic behavior of the peptide. While CJC-1295 without DAC exhibits a rapid clearance profile suitable for transient signaling assays, CJC-1295 DAC demonstrates an extended elimination half-life exceeding 6 days in published mammalian studies. This continuous systemic circulation leads to sustained elevated basal GH and downstream hepatic IGF-1 release.
Choosing between the two variants depends entirely on the experimental model. Research investigating natural physiological GH pulsatility, receptor resensitization, or acute pituitary responsiveness typically utilizes CJC-1295 without DAC. Conversely, studies targeting continuous elevated tissue exposure or long-term nitrogen retention models may utilize the DAC-bound variant. Investigators can browse the full range of modified secretagogues in the PX1 Research peptide catalog.
A major area of interest in somatotroph physiology involves co-evaluating GHRH analogs alongside selective ghrelin receptor agonists. Researchers frequently structure protocols combining CJC 1295 without DAC and Ipamorelin to examine potential synergistic pathways in growth hormone secretion.
Ipamorelin acts as a highly selective agonist at the growth hormone secretagogue receptor 1a (GHSR-1a). While CJC-1295 activates the cAMP/PKA cascade via GHRHR, Ipamorelin stimulates the phospholipase C (PLC) and inositol trisphosphate (IP3) pathway, releasing intracellular calcium stores. When both receptors are stimulated simultaneously in somatotroph cell cultures or animal models, the combined signaling produces a amplified release of GH that exceeds the additive sums of either compound administered independently.
Crucially, preclinical assays indicate that co-administering these two selective agents maintains receptor specificity without triggering significant off-target elevations in adrenocorticotropic hormone (ACTH), cortisol, or prolactin. Researchers exploring dual secretagogue mechanisms can reference additional structural data in the PX1 peptide research center.
When designing comparative secretagogue protocols, laboratories frequently evaluate CJC-1295 variants against alternative GHRH derivatives and GHRP compounds to map distinct signaling dynamics and stability profiles.
Sermorelin represents the truncated 1-29 amino acid sequence of native GHRH without the four stabilizing amino acid substitutions present in modified GRF 1-29. In cellular models, Sermorelin displays rapid cleavage by DPP-IV enzymes, resulting in a half-life of 10 to 12 minutes. This makes it an excellent control for baseline enzymatic degradation studies. Researchers evaluating these kinetics can compare structural parameters against alternative compounds in our GHRH research library.
Tesamorelin is another GHRH derivative incorporating a trans-3-hexenoic acid group at the N-terminus, engineered specifically for enhanced metabolic stability in lipodystrophy models. Meanwhile, GHRP-2 and GHRP-6 provide contrasting GHSR agonist profiles to Ipamorelin, though with varying degrees of secondary cortisol and prolactin stimulation. Access to verified, high-purity batches of these related agents is available through our dedicated research secretagogues section.
Selecting a reliable research supplier requires rigorous verification of analytical documentation. Because synthetic peptide synthesis can yield truncation sequences, incomplete deprotection artifacts, and residual trifluoroacetic acid (TFA) salts, purchasing agents must demand comprehensive chemical testing prior to placing orders.
A critical red flag in peptide procurement is relying on generalized or outdated certificates of analysis. Unscrupulous vendors frequently display a single 'representative' COA across multiple production batches or hide behind unverified internal mass spectrum charts that lack independent laboratory verification. Furthermore, many vendors fail to perform quantitative endotoxin testing, risking contaminated reagents that can corrupt sensitive cell culture viability or provoke non-specific immune responses in animal assays.
Reputable vendors ensure every lot undergoes independent third-party analysis using high-resolution RP-HPLC for purity and Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF) or ESI Mass Spectrometry for sequence mass confirmation. PX1 Research publishes lot-specific analytical reports accessible directly to researchers, establishing a transparent standard for institutional research.
To streamline vendor qualification for institutional procurement officers and principal investigators, the following matrix outlines the key technical standards necessary for reproducible research:
- Purity Verification: Mandatory RP-HPLC testing demonstrating ≥98.0% peptide purity with clear, fully integrated peak charts.
- Identity Confirmation: Electrospray ionization mass spectrometry (ESI-MS) or MALDI-TOF confirming correct theoretical monoisotopic mass.
- Endotoxin Testing: Quantitative Chromogenic LAL assay verifying endotoxin levels below 0.01 EU/mg to prevent cell culture toxicity.
- Lot Traceability: Individual vial lot numbers directly corresponding to downloadable, independent third-party COAs.
- Sourcing & Synthesis: Solid-phase peptide synthesis (SPPS) performed under controlled US laboratory manufacturing standards.
- Logistics & Storage: Temperature-controlled packaging and same-day dispatch from established domestic fulfillment hubs in CA and AZ.
- Technical Support: Responsive support manned by specialists equipped to handle bulk inquiries and institutional procurement through our wholesale peptide division.
Maintaining structural integrity during reconstitution is essential for experimental accuracy. Lyophilized CJC-1295 without DAC is supplied as a sterile, vacuum-sealed cake or powder. Prior to reconstitution, vials should be stored at -20°C for long-term stability or 2°C to 8°C for short-term bench preservation.
Reconstitution should be performed using sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) or sterile normal saline depending on assay requirements. The solvent should be introduced gently along the glass vial wall rather than sprayed directly onto the peptide cake to prevent agitation-induced mechanical shear and aggregation. Allow the cake to dissolve naturally without vigorous shaking.
Once reconstituted in solution, CJC-1295 without DAC exhibits reduced stability relative to its dry state. Reconstituted aliquots must be stored at 2°C to 8°C and utilized within 21 to 28 days. For extended experimental timelines, reconstituted solutions should be aliquoted into single-use polypropylene tubes and frozen at -80°C to avoid repeated freeze-thaw cycles that break peptide bonds.
When purchasing CJC-1295 without DAC or complementary research compounds from PX1 Research, laboratory buyers receive fully vetted reagents backed by rigorous quality assurance. Each order ships in secure, tamper-evident vials containing precisely weighed 2 mg or 5 mg lyophilized units designed to maximize benchtop convenience and minimize waste.
Orders placed before 3:00 PM EST Monday through Friday are processed and dispatched same-day from our dual fulfillment centers in California and Arizona. Every shipment includes full tracking details, cold-pack temperature protection when required, and direct digital access to the lot-specific certificate of analysis.
Our dedicated customer service team provides rapid assistance for procurement logistics, custom lot reservations, and institutional billing. To secure analytical-grade material for your next investigative study, order CJC-1295 without DAC vials directly from our online catalog.
Is CJC-1295 DAC legal to buy in the United States?
Yes. CJC-1295 DAC and CJC-1295 without DAC are legally available in the United States as non-controlled research chemicals. They can be lawfully purchased by universities, private laboratories, and independent researchers strictly for in vitro testing and animal model studies.
What is the primary difference between CJC-1295 with DAC and CJC-1295 without DAC?
The primary difference lies in systemic half-life. The Drug Affinity Complex (DAC) allows CJC-1295 to bind to circulating serum albumin, extending its biological half-life to several days. CJC-1295 without DAC lacks this complex, resulting in a rapid 30-minute half-life ideal for studying discrete pulsatile GH release.
Why do researchers study CJC 1295 without DAC and Ipamorelin together?
Combining CJC-1295 without DAC (a GHRH analog) and Ipamorelin (a selective GHRP/ghrelin receptor agonist) stimulates two distinct intracellular pathways in somatotrophs. Preclinical assays show this dual activation creates a synergistic, amplified growth hormone release without causing significant elevations in cortisol or prolactin.
Does PX1 Research provide a COA for my specific CJC-1295 lot?
Yes. PX1 Research includes a lot-specific third-party Certificate of Analysis (COA) with every purchase. The document confirms peptide identity via mass spectrometry, purity level via RP-HPLC (verifying ≥98% purity), and verifies endotoxin safety thresholds.
What purity level is guaranteed for CJC-1295 without DAC?
PX1 Research guarantees a minimum purity of 98.0% for CJC-1295 without DAC as measured by high-performance liquid chromatography (RP-HPLC). Analytical testing documentation is publicly accessible prior to ordering.
How fast does PX1 Research ship peptide orders?
Orders placed before 3:00 PM EST Monday through Friday dispatch same-day from our fulfillment facilities located in California and Arizona. Domestic orders arrive via tracked priority shipping within 2 to 4 business days.
How should CJC-1295 without DAC be stored upon arrival?
Lyophilized CJC-1295 without DAC should be stored in a freezer at -20°C for long-term preservation, or refrigerated at 2°C to 8°C for short-term use. Once reconstituted, solutions must be kept refrigerated and used within 28 days.
Is CJC-1295 approved by the FDA for human clinical use?
No. Neither CJC-1295 DAC nor CJC-1295 without DAC is approved by the FDA for human administration, clinical therapy, or personal medical use. All products sold by PX1 Research are strictly for laboratory research use only.
What solvent is recommended for reconstituting CJC-1295 vials?
Laboratories typically utilize sterile Bacteriostatic Water (0.9% benzyl alcohol) for reconstitution when multi-dose sampling is required over several weeks, or sterile 0.9% sodium chloride for immediate single-assay applications.
Can institutions order bulk quantities of research peptides from PX1 Research?
Yes. Institutional buyers and research organizations can submit volume procurement inquiries through our wholesale division to arrange bulk lot reservations, custom synthesis runs, and standardized institutional pricing.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.